{"id":62695,"date":"2012-12-06T23:03:10","date_gmt":"2012-12-06T23:03:10","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/independence-blue-cross-penn-medicine-announce-philadelphia-health-care-accelerator.php"},"modified":"2012-12-06T23:03:10","modified_gmt":"2012-12-06T23:03:10","slug":"independence-blue-cross-penn-medicine-announce-philadelphia-health-care-accelerator","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/medicine\/independence-blue-cross-penn-medicine-announce-philadelphia-health-care-accelerator.php","title":{"rendered":"Independence Blue Cross, Penn Medicine Announce Philadelphia Health Care Accelerator"},"content":{"rendered":"<p><p>    PHILADELPHIA, Dec. 5, 2012 (GLOBE NEWSWIRE) --     Independence Blue Cross (IBC) and Penn Medicine (The    University of Pennsylvania Health System) today announced that    they are teaming up with DreamIt Ventures to sponsor the    first-ever Philadelphia-based health care \"accelerator,\" an    organization that will jump start new companies developing    innovative solutions in health care. Designed to help promising    health care startups rapidly accelerate the development of new    products and high impact business models, the accelerator will    provide cash, guidance from experienced health care executives    and entrepreneurs, office space, and more to 10 young companies    selected for a four-month boot camp.  <\/p>\n<p>    This collaboration marks the first time a leading health    insurer and a leading health care provider have come together    to offer entrepreneurs the resources they need to capitalize on    emerging health care opportunities.  <\/p>\n<p>    The accelerator is named DreamIt Health, powered by IBC and    Penn Medicine.  <\/p>\n<p>    DreamIt Health will accept applications from today through    February 8 from startups nationwide in the health care sector,    and on March 8 will select 10 early-stage companies that have    strong founders, innovative products or services, and    entrepreneurial passion to participate. During the four-month    boot camp, from April to July 2013, the companies will work in    space at Venturef0rth in Philadelphia, whose offices are    specifically designed to house and support startup companies.  <\/p>\n<p>    The accelerator will give each selected company a stipend of up    to $50,000 plus in-depth mentoring, coaching from experts, and    access to other critical health care-specific resources to    rapidly develop and test its product, validate its business    model with potential customers, and get the company organized    and ready to pitch to investors. The program will culminate in    a \"demo day\" when the 10 companies will present their    businesses to an audience of leading investors and health care    organizations.  <\/p>\n<p>    \"At Independence Blue Cross, we believe that innovation is the    key to bringing fresh ideas into health care and truly changing    the game,\" said IBC President and CEO Daniel J. Hilferty. \"From    the     IBX Game Changers Challenge to creating DreamIt Health, we    are committed to transforming the Philadelphia region into a    national magnet for health care innovation, investment, and    employment.\"  <\/p>\n<p>    As the Philadelphia region's leading health insurer and leading    health system, respectively, IBC and Penn Medicine are uniquely    positioned to provide contacts, a potential customer's    perspective, and resources like access to data and technology    that health care startups need to succeed.  <\/p>\n<p>    \"We are deeply committed to translating strategies from    discovery to application in clinical practice,\" stated    University of Pennsylvania Health System CEO Ralph Muller.    \"Through the partnership of Penn Medicine and IBC on DreamIt    Health, we have established a collaborative relationship    between the health insurer and the health system, eliminating    the usual obstacles to health care innovation.\"  <\/p>\n<p>    With DreamIt's unparalleled network of mentors and its proven    curriculum that guides the growth of young technology    companies, participants in the accelerator will have the    opportunity to rapidly build out their products and services    using claims and clinical data as well as other resources. By    acquiring potential customer validation, participating    companies will be able to accelerate their progress toward    raising capital and launching to a broader marketplace. DreamIt    has launched 80 companies over the past four years (15 more in    Philadelphia in the current session) who have raised over $80    million in follow-on investment capital with an enterprise    value of close to $330 million.  <\/p>\n<p>    The accelerator encourages applications from companies    nationwide that take a broad view of working across the health    care industry, including health insurers, physicians,    hospitals, and others in the health care industry, to apply    technology to the challenges of proactively keeping people    healthy, as well as providing more effective and affordable    interventions when people get sick. The accelerator seeks    applicants nationwide that \"think big\" and want to take    advantage of the resources that come with this unique    collaboration among a health insurer, a health system, and    DreamIt.  <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>Link:<\/p>\n<p><a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/independence-blue-cross-penn-medicine-192407964.html;_ylt=A2KJ3CcWJMFQ_RgARTr_wgt.\" title=\"Independence Blue Cross, Penn Medicine Announce Philadelphia Health Care Accelerator\">Independence Blue Cross, Penn Medicine Announce Philadelphia Health Care Accelerator<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> PHILADELPHIA, Dec.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/medicine\/independence-blue-cross-penn-medicine-announce-philadelphia-health-care-accelerator.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[35],"tags":[],"class_list":["post-62695","post","type-post","status-publish","format-standard","hentry","category-medicine"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/62695"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=62695"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/62695\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=62695"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=62695"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=62695"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}